Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.91 USD | +6.45% | +34.12% | +20.66% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.66% | 665M | |
-0.78% | 102B | |
+3.26% | 96.09B | |
+2.13% | 22.28B | |
-15.31% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.07% | 16.09B | |
+7.24% | 13.83B | |
+35.65% | 11.97B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- Raymond James Downgrades AnaptysBio to Market Perform From Outperform